Review on sodium glucose co-transporter-2 inhibitors for treatment of type-2 diabetes mellitus

Sodium glucose transporter-2 inhibitors (SGLT2-i) are a class of medicine that have been recently acknowledged and approved for management of Type-2 Diabetes Mellitus (T2DM). They have distinct encouraging extra-pancreatic glucuretic role that has been clinically applied for blood sugar management. Reports have been published for multiple side effects including ketoacidosis & ketonuria induced by SGLT2-i. This endeavor delves into the pharmacokinetics of SGLT-i agents, deliberates the utility of these drugs and suggests steps to maximize the safe use of these agents including their diverse beneficial effects.